ERBB2 and breast carcinoma: However, the current guidelines of the American Society of Clinical Oncology (ASCO) suggest the use of a combination of trastuzumab, pertuzumab and a taxane for first-line treatment and the use of T-Dxd if HER2-positive advanced breast cancer has progressed during or after first-line HER2-targeted therapy [7].